On October 27, approximately 310 people gathered at the Mill Casino in North Bend, Oregon to learn from and connect with state and local leaders, identify specific challenges in Coos, Curry and Josephine counties and begin drafting an action plan to turn the tide of opioid abuse, misuse and overdose in the region. This was the best attended of the five regional summits hosted by OrCRM to date. Turnout for the SW Oregon Opioid Summit included organizations representing medical, pharmacy, dental, behavioral health, addictions, law enforcement, education, and tribal communities as well as interested citizens.
Click here to view speaker presentations and information about the summit
The Coalition was launched at the behest of the Governor and Oregon Health Authority to conveneregional summits to implement Regional Action Plans that address four core strategies:
- Reduce pills in circulation through improved prescribing practices, use of the Oregon Prescription Drug Monitoring Program, increased access to non-opioid therapies, and prescriber education
- Reduce the volume of disused pills through access to safe disposal of unused medication
- Expand access to medication for evidence-based opioid agonist and antagonist therapy and overdose rescue
- Improve public education on opioid risks and dangers.
We have developed a diverse and effective coalition with significant capacity for change. Membership includes leading community players from medical providers to health systems to law enforcement to treatment and prevention professionals to public health.
OrCRM’s role in reducing Oregon’s prescription drug epidemic is that of convener and change agent – moving discussion into action. We have become both a resource and leader on this issue through our proven ability to mobilize and engage a wide range of stakeholders. These efforts have built momentum and capacity to implement regional and statewide strategies. Beginning in April 2015, the Coalition has hosted five regional summits in collaboration with CCO’s and other stakeholders with more than 600 participants. Data suggests declines in opioid prescriptions and reduced overdose rates.